Ovarian Cancer

Outsmarting Ovarian cancer - Discovering the missing link

The future is now! 

1. Cell based immunotherapy; personalised vaccines made from your own immune system.

2. Cell based immunotherapy in combination with personalised vaccines created from your own tumour (called tumour lysate).

Individualised immunotherapy is the future

“ Individualised immunotherapy is the future, as each patient’s disease has unique features and non-synonymous mutations that can be targeted”.

Says a study supported by grants from the National institutes of Health, the Marcus Foundation & the Ovarian Cancer Immunotherapy initiative reported:

The Future is now!
Contact us to discover more about cell-based immunotherapy and how it can be used to target ovarian cancer

Grace Gawler says: “I encourage you to be a participant in your own ovarian cancer treatment & health restoration program. Before your treatments begin, make sure you understand all your options and the possible outcomes”.
Immunotherapy: Due to failure to treat ovarian cancers with immune checkpoint inhibitors, it was believed that they were non-responsive to immunotherapy, which means not readily penetrated by anti-tumour T cells.
However recent research has shown that ovarian cancers often express a range of tumour associated antigens and T cell infiltration which often equates with better patient survival.

A significant addition - Immunotherapy treatment for ovarian cancer.

The Grace Gawler Institute for Survivorship & Research via our Navigation Services; can direct you to a significant value-add immunotherapy treatment for ovarian cancer.

A special type of immunotherapy that seems to be most effective is made from harvesting your own immune cells; safely proliferating them in the laboratory (without genetic engineering) and then giving back to you as a personalised immunotherapy vaccine. 
If tumour tissue can be safely harvested and prepared; then it provides a substantial volume of tumour ‘intel’ and ‘codes’ that can be read, interpreted and actioned by your body’s own immune-surveillance system.

Help outsmart ovarian cancer as early as possible in your diagnosis / treatment protocol – discover how cell-based immunotherapy can help you!  

Ovarian Cancer benefits from new approaches such as cell-based immunotherapy

Why Ovarian Cancer benefits from new approaches such as cell-based immunotherapy:
• Ovarian cancer often has no symptoms during the early stages, so the disease is generally advanced and metastasised when first diagnosed.
• Ovarian cancer exhibits unusual behaviour because it is a cancer where first line treatment usually eliminates the cancer for a period of time, but recurrence occurs often.
• The standard treatment for ovarian cancer consists of debulking surgery followed by six rounds of chemotherapy. One recent study found that ONLY 37 percent of women receive this standard treatment, despite evidence showing that it is the most effective in conventional oncology medicine.
• Because of the nature & behaviour of the disease, all patients with ovarian cancer should know about cell-based immunotherapy after standard treatment so they can be informed and make a choice that could significantly impact survivorship.

There are three types of ovarian tissue that can produce cancers:

About Ovarian Cancer:

Did you know there are three types of ovarian tissue that can produce cancers:
*epithelial cells, linings which cover the ovary
*stromal cells, which produce hormones;
* germ cells, which become ova (eggs).
About 85 to 90 per cent of ovarian cancers are epithelial carcinomas.

What makes women vulnerable to Ovarian cancer?

Read More
     


Ovulation cycles causes the ovarian surface layer to undergo repeated disruption and repair with cells regularly stimulated to proliferate, which increases the probability of spontaneous DNA mutations. The ovaries present a unique pro-inflammatory microenvironment, that likely increases the rate of DNA damage, thus increasing cancer risk.
Most ovarian cancers occur spontaneously, although 5–10 per cent of cases develop due to a genetic predisposition (hereditary). The latter, involving dysfunctional BRCA1 or BRCA2 genes, produces high-grade ovarian carcinomas.  
More recently the use of Talcum powder contaminated with asbestos has been linked to Ovarian cancers as well as lifestyle factors, HRT and smoking the latter increases risk of mucinous ovarian cancer.

Be empowered with Genomic testing  for ovarian cancer:

Genomic testing can be used to analyse the DNA of your tumour and may identify the genetic mutations that are unique to your “brand” of ovarian cancer. This is especially useful when looking for targeted treatments for ovarian cancer, for BRCA1,2,  Sometimes specific genomic tests can identify if immunotherapy can be effective for you. It is also important to know if you have resistance to chemotherapy. Chemotherapy resistance  in ovarian cancer patients has shown to be associated with inactivating gene breakages at the level of the tumour suppressor genes which may help guide treatment choices. 

Every ovarian cancer patient deserves an accurate diagnosis

Grace Gawler InstituteIdentifying the mutations in a patient’s cancer is the key to developing personalised treatments.

Clinical trials have shown that personalised therapies, developed from genetic testing of tumours, are the most effective way to improve treatment outcomes.
Patients undertaking therapy as a result from genetic testing are shown to have longer progression-free, higher response rates to treatment and overall greater survival rates. Ask Grace …..